Vokes, Everett E.
University of Chicago Medical Center
11 papers on CoChatORCID 0000-0002-8645-8068
Most cited papers
- Verified
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 9,335
- Verified
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 8,447
- Verified
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine
Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers
Cited by 5,101
- Verified
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology
Head and Neck Cancer StudiesHER2/EGFR in Cancer Research
Cited by 807
- Verified
Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer
Adjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 219
- Verified
Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology
Dolezal, J. M., Srisuwananukorn, A., Karpeyev, D., Ramesh, S., Kochanny, S., Cody, B., Mansfield, A. S., Rakshit, S., Bansal, R., Bois, M. C., et al. (2022) · Nature Communications
AI in cancer detectionRadiomics and Machine Learning in Medical Imaging
Cited by 147
- Verified
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Spicer, J., Wang, C., Tanaka, F., Saylors, G. B., Chen, K.-N., Liberman, M., Vokes, E. E., Girard, N., Lu, S., Provencio, M., et al. (2021) · Journal of Clinical Oncology
Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 139
- Verified · note
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., Agamah, E., Stadler, W. M., & Vokes, E. E. (2012) · Investigational New Drugs
Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment
Cited by 103
- Verified
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
Sharma, M. R., Wroblewski, K., Polite, B. N., Knost, J. A., Wallace, J. A., Modi, S., Sleckman, B. G., Taber, D., Vokes, E. E., Stadler, W. M., et al. (2012) · Investigational New Drugs
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 49
- Verified
Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.
Foster, C. C., Kochanny, S., Khattri, A., Acharya, R., Dekker, A., Tan, Y.-H. C., Klema, E., Brisson, R. J., Saloura, V., Pearson, A. T., et al. (2018) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersHead and Neck Cancer Studies
Cited by 28
- Verified
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101
Jelinek, M. J., Foster, N. R., Zoroufy, A. J., Schwartz, G. K., Munster, P. N., Seiwert, T. Y., de Souza, J. A., & Vokes, E. E. (2021) · Oral Oncology
Head and Neck Cancer StudiesPARP inhibition in cancer therapy
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free